KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 151–167 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12D3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2251 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2252 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 16497971 · Hoang et al., 2006 · Open in CIViC	civic
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID937 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic
KRAS G12C4
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2261 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2262 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS G12S3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2277 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2278 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS RS617643701
Carboplatin + PaclitaxelSubstitutes	Ovarian CarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID664 The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC) PMID 22139083 · Ratner et al., 2012 · Open in CIViC	civic
KRAS G12/G132
Gemcitabine + TrametinibCombination	Pancreatic Adenocarcinoma	Predictive	B	Supports Resistance	4	accepted	EID622 Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastati… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
Trametinib	Pancreatic Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID990 KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
KRAS Mutation1
PI3Kbeta Inhibitor AZD8186 + SCH772984Combination	Pancreatic Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1003 Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC) PMID 26725216 · Hayes et al., 2016 · Open in CIViC	civic
KRAS Exon 2 Mutation1
Erlotinib	Pancreatic Carcinoma	Predictive	B	Does Not Support Resistance	3	accepted	EID916 KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment. PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7492 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7493 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

emaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Atezolizumab	EU EMA	—	Urothelial carcinoma Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy (see section 5.1 for selection criteria).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancer (SCLC)Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1). Triple-negative breast cancer (TNBC)Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1). Urothelial carcinoma (UC) Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC: after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK positive NSCLC (see section 5.1 for selection criteria). Advanced NSCLC  Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate target…

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,651)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 795 recruiting · 365 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1,001–1,050 of 1,651 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03377023	Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer	active not recruiting	Phase 1 / Phase 2	66	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Apr 2, 2026	clinicaltrials
NCT05733598	Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC	recruiting	Phase 2	60	Replimune, Inc.INDUSTRY	1	Apr 2, 2026	clinicaltrials
NCT02873962	A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib	active not recruiting	Phase 2	72	Dana-Farber Cancer InstituteOTHER	1	Apr 1, 2026	clinicaltrials
NCT04486352	A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer(EndoMAP)	recruiting	Phase 1 / Phase 2	148	Alliance Foundation Trials, LLC.OTHER	1	Apr 1, 2026	clinicaltrials
NCT04498117	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5)	active not recruiting	Phase 3	615	CanariaBio Inc.INDUSTRY	14	Apr 1, 2026	clinicaltrials
NCT05605535	Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer	active not recruiting	Phase 2	88	CanariaBio Inc.INDUSTRY	1	Apr 1, 2026	clinicaltrials
NCT05735080	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01)	recruiting	Phase 1 / Phase 2	150	Incyclix BioINDUSTRY	2	Apr 1, 2026	clinicaltrials
NCT05769010	Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases	recruiting	Phase 2	150	Henan Cancer HospitalOTHER_GOV	1	Apr 1, 2026	clinicaltrials
NCT06295159	Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma	recruiting	Phase 2	90	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Apr 1, 2026	clinicaltrials
NCT04654208	Swedish Ibrance Registries Insights (SIRI)(SIRI)	recruiting	—	1,500	PfizerINDUSTRY	1	Mar 31, 2026	clinicaltrials
NCT04963283	Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	active not recruiting	Phase 2	48	University of Colorado, DenverOTHER	1	Mar 31, 2026	clinicaltrials
NCT01525966	Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer	active not recruiting	Phase 2	67	City of Hope Medical CenterOTHER	1	Mar 30, 2026	clinicaltrials
NCT04129502	TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations	active not recruiting	Phase 3	354	TakedaINDUSTRY	24	Mar 30, 2026	clinicaltrials
NCT04703101	Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer	recruiting	Phase 1	25	Jonsson Comprehensive Cancer CenterOTHER	1	Mar 30, 2026	clinicaltrials
NCT05160922	Crizotinib Continuation Clinical Study	active not recruiting	Phase 4	27	PfizerINDUSTRY	5	Mar 30, 2026	clinicaltrials
NCT05984602	A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer	active not recruiting	Phase 1	9	NYU Langone HealthOTHER	1	Mar 30, 2026	clinicaltrials
NCT06868732	Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC	recruiting	Phase 1	288	Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY	1	Mar 30, 2026	clinicaltrials
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR)	recruiting	Phase 2	720	Canadian Cancer Trials GroupNETWORK	1	Mar 27, 2026	clinicaltrials
NCT03568422	CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer	active not recruiting	Phase 1 / Phase 2	37	Canadian Cancer Trials GroupNETWORK	1	Mar 27, 2026	clinicaltrials
NCT07495098	Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer	not yet recruiting	Phase 1	12	University of VermontOTHER	0	Mar 27, 2026	clinicaltrials
NCT04930783	NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma	active not recruiting	Phase 1	10	Dana-Farber Cancer InstituteOTHER	1	Mar 25, 2026	clinicaltrials
NCT04008797	A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor	active not recruiting	Phase 1 / Phase 2	301	Eisai Inc.INDUSTRY	10	Mar 24, 2026	clinicaltrials
NCT04095364	Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 3	450	NRG OncologyOTHER	6	Mar 24, 2026	clinicaltrials
NCT05805631	Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC	recruiting	Phase 2	23	Taipei Veterans General Hospital, TaiwanOTHER_GOV	1	Mar 24, 2026	clinicaltrials
NCT07335081	ctDNA in HER2+ EBC Neoadjuvant Treatment	recruiting	Phase 2	60	Shanghai Jiao Tong University School of MedicineOTHER	1	Mar 24, 2026	clinicaltrials
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	recruiting	Phase 2	60	Roswell Park Cancer InstituteOTHER	1	Mar 23, 2026	clinicaltrials
NCT07125755	Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma	recruiting	Phase 3	386	Sun Yat-sen UniversityOTHER	1	Mar 23, 2026	clinicaltrials
NCT04894643	Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer(PARC)	recruiting	N/A	10	EBG MedAustron GmbHINDUSTRY	1	Mar 20, 2026	clinicaltrials
NCT06357975	Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)	active not recruiting	Phase 2	44	National Cancer Institute (NCI)NIH	1	Mar 19, 2026	clinicaltrials
NCT06497985	A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients	recruiting	Phase 3	430	Chipscreen Biosciences, Ltd.INDUSTRY	1	Mar 19, 2026	clinicaltrials
NCT04379635	Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)	active not recruiting	Phase 3	453	BeiGeneINDUSTRY	1	Mar 18, 2026	clinicaltrials
NCT04904588	HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS)	active not recruiting	Phase 2	300	Center for International Blood and Marrow Transplant ResearchNETWORK	1	Mar 18, 2026	clinicaltrials
NCT05101070	S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors(aCCeleR8-001)	recruiting	Phase 1 / Phase 2	282	ShionogiINDUSTRY	2	Mar 18, 2026	clinicaltrials
NCT06804824	A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors	recruiting	Phase 1	220	Vividion Therapeutics, Inc.INDUSTRY	2	Mar 18, 2026	clinicaltrials
NCT03384238	Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery	recruiting	Phase 1 / Phase 2	27	George PoultsidesOTHER	1	Mar 17, 2026	clinicaltrials
NCT05194995	JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation	active not recruiting	Phase 1 / Phase 2	48	Allist Pharmaceuticals, Inc.INDUSTRY	1	Mar 16, 2026	clinicaltrials
NCT05528952	Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO)	recruiting	Phase 2	105	Centre Hospitalier Universitaire de BesanconOTHER	1	Mar 16, 2026	clinicaltrials
NCT07176650	Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma	recruiting	Phase 1	246	Shanghai Henlius BiotechINDUSTRY	2	Mar 16, 2026	clinicaltrials
NCT06736704	SNV4818 in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	320	Pikavation Therapeutics, Inc.INDUSTRY	3	Mar 13, 2026	clinicaltrials
NCT03970096	Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	recruiting	Phase 2	120	Fred Hutchinson Cancer CenterOTHER	1	Mar 12, 2026	clinicaltrials
NCT04417621	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	active not recruiting	Phase 2	134	Novartis PharmaceuticalsINDUSTRY	12	Mar 12, 2026	clinicaltrials
NCT07466160	A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	280	Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY	1	Mar 12, 2026	clinicaltrials
NCT05524584	Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer	recruiting	Phase 2	20	University of California, IrvineOTHER	1	Mar 11, 2026	clinicaltrials
NCT07464327	A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations	not yet recruiting	Phase 3	450	Hansoh BioMedical R&D CompanyINDUSTRY	0	Mar 11, 2026	clinicaltrials
NCT05378334	Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients	recruiting	N/A	82	Guangzhou University of Traditional Chinese MedicineOTHER	1	Mar 10, 2026	clinicaltrials
NCT06821503	Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C	recruiting	Phase 1 / Phase 2	72	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY	1	Mar 10, 2026	clinicaltrials
NCT07461675	Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection	not yet recruiting	Phase 3	30	University of Geneva, SwitzerlandOTHER	1	Mar 10, 2026	clinicaltrials
NCT03999749	A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma	active not recruiting	Phase 2	71	NYU Langone HealthOTHER	1	Mar 9, 2026	clinicaltrials
NCT04020809	Neoadjuvant Atezolizumab in Cutaneous Melanoma	active not recruiting	Phase 1	20	The Methodist Hospital Research InstituteOTHER	1	Mar 9, 2026	clinicaltrials
NCT04393285	Abemaciclib and Letrozole to Treat Endometrial Cancer	active not recruiting	Phase 2	53	Gynecologic Oncology GroupNETWORK	1	Mar 9, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,651)

Linked publications (113)